1 citations
,
January 2026 in “International Journal of Dermatology” In this case series, three patients with advanced non-small cell lung cancer experienced severe skin eruptions and scarring alopecia after treatment with amivantamab, highlighting the critical need for prompt recognition and management of these adverse effects to minimize treatment interruptions.
June 2026 in “British Journal of Dermatology” This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.
In this study, researchers found that female rats exhibited more pronounced panic-related escape behavior during hypoxia, particularly in the diestrus phase, and that low-dose fluoxetine reduced this behavior, suggesting its potential for managing panic disorder symptoms related to hormonal cycles in women.
3 citations
,
May 2016 in “Journal of Cutaneous Medicine and Surgery” This article briefly describes local anesthesia techniques for hair restoration surgery that aim to enhance patient comfort but reports no new research results.
July 2026 in “Frontiers in Oncology” This mini review reports on papulopustular eruptions linked to classical EGFR inhibitors, MEK inhibitors, and amivantamab, highlighting distinct dermatologic toxicities in each treatment context and exploring underlying mechanisms and management strategies.